Deal Details

Praxis Completes $661.4 Million Follow-On Offering

Healthcare

Praxis follow-on offering

Summary

Praxis Precision Medicines, Inc. (“Praxis”) (NASDAQ: PRAX), recently completed an underwritten public offering (the “Offering”) of 2,543,800 shares, including the full exercise of the underwriters’ option to purchase additional shares of common stock, at a price of $260.00 per share, generating gross proceeds of approximately $661.4 million.

Baird served as a lead manager on this Offering.

About

Praxis is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using its understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. Praxis is headquartered in Boston, Massachusetts.

Healthcare

Praxis follow-on offering